Roche to buy InterMune for $8.3 billion

Roche says it will pay $8.3 billion for a California biotech firm that has yet to turn a profit on a new drug to treat a deadly lung disease, the latest gamble by a pharmaceutical giant to buy its way into a lucrative corner of the industry.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.